Healthy Families PrEP for Women at Risk for HIV
Part of Infections, Women’s health & pregnancy clinical trials.
This study tests a program to help women at risk for HIV get PrEP, a medicine that prevents HIV. It focuses on women who may want to have a child or have been pregnant recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You do not have HIV, but you are at risk, for example if your partner has HIV or may have HIV.
- You have been pregnant in the last 2 years, or you want to have a child in the next year, or your partner wants a child in the next year.
- You speak English or the local language fluently.
- You live within 60 kilometers (about 37 miles) of a healthcare center in the trial.
- You are willing to sign a consent form and take an HIV test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers different forms of HIV prevention medicine (PrEP) to young women ages 18–30 who are visiting clinics for reproductive health services like family planning or postnatal care. It aims to see which delivery method works best for you.
This study looks at offering HIV prevention medicines (PrEP) to patients visiting a family planning clinic. It aims to make it easier for people to access this care alongside their regular visit.
This study aims to expand access to PrEP (a daily pill that prevents HIV) for pregnant and postpartum women visiting maternal and child health clinics in Kenya. It also includes health care workers who provide PrEP services.
This study tests a program called PrEP Choice to help young people learn about and start PrEP, a daily pill that prevents HIV. It aims to see if offering choices in PrEP care makes it easier to use.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.